Collectively, these data indicate the β-catenin:MSI2 interaction could occur frequently across primary AML samples and could be clinically relevant given the association of both proteins with inferior survival in AML [11, 52, 53]. This evidence concerns the gene MSI2 and acute myeloid leukemia.